What is Regeneron Pharmaceuticals's current debt?

Regeneron Pharmaceuticals (REGN) reported current debt of $720M in Q2 2026.

What does current debt mean?

The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Regeneron Pharmaceuticals REGN Current Debt

Current Debt at other companies

AmgenAMGN

$5.44B+61.4%

Kymera TherapeuticsKYMR

$1.7M+9.1%

Other financials

Income statement

See full

Revenue$4.3B+16.7%

Operating income$1.3B+19.8%

Net income$1.3B-6.8%

EPS (diluted)$12.23-4.5%

Balance sheet

See full

Cash & equivalents$2.5B+22.3%

Total debt$2.7B+0.1%

Total equity$31.7B+5.9%

Total assets$41.7B+9.2%

Cash flow

See full

Operating cash flow$813.0M-29.0%

CapEx$240.2M+9.7%

Free cash flow$572.8M-38.1%

Valuation

See full

Market cap$72.88B+20.9%

Enterprise value$73.12B+20.0%

P/E16.8×+3.3×

P/S4.7×+0.5×

Profitability

See full

Gross margin94.9%—

Operating margin24.7%-2.3pp

Net margin27.9%-3.5pp

FCF margin24.2%-2.9pp

Returns & leverage

See full

Return on equity14%-1.3pp

Debt / equity0.1×0.0×

Current ratio3.3×-1.3×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regeneron Pharmaceuticals's current debt?: Regeneron Pharmaceuticals (REGN) reported current debt of $720M in Q2 2026.
What does current debt mean?: The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.